Jason Davis - 02 Mar 2026 Form 4 Insider Report for FibroBiologics, Inc. (FBLG)

Reporting relationship: Chief Financial Officer
Issuer ticker: FBLG
Reported as of: 02 Mar 2026
Net transaction value: +$28,973
SEC form: 4
Accepted by SEC: 03 Mar 2026, 08:00:20 UTC
Prior SEC filing: 10 Jun 2025
Next SEC filing: 18 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Ruben A. Garcia, by Power of Attorney

Key filing fact

Jason Davis filed Form 4 for FibroBiologics, Inc. (FBLG) on 03 Mar 2026.

Key facts

This page summarizes Jason Davis's Form 4 filing for FibroBiologics, Inc. (FBLG).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 03 Mar 2026, 08:00.

Change

Previous filing in this sequence was filed on 10 Jun 2025.
Current net transaction value: +$28,973.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001443533 Primary reporting owner

Davis Jason

Relationship: Chief Financial Officer
Address: C/O FIBROBIOLOGICS, INC., 455 E. MEDICAL CENTER BLVD., SUITE 300, HOUSTON,
Signature: /s/ Ruben A. Garcia, by Power of Attorney
Signature date: 03 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

FBLG transaction

Common Stock

Purchase

Transaction value: $28,973
Shares: +70,000
Change %
Price: $0.4139
Shares after: 70,000
Date: 02 Mar 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $0.3968 to $0.4200 on March 2, 2026. The reporting person will provide upon request to the SEC, the Issuer, or security holder of the Issuer, full information regarding the number of shares purchased at each separate price.